BMO Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) but lowers the price target from $70 to $63.

April 01, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital maintains an Outperform rating on 4D Molecular Therapeutics but lowers the price target from $70 to $63.
While the reduction in price target from $70 to $63 could suggest a tempered outlook, the maintenance of an Outperform rating indicates continued confidence in the company's fundamentals. This mixed signal might lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the analyst's ongoing positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100